PF4 and systemic sclerosis: In this pilot study, we analyzed a series of experimental immunological parameters linked to CXCL4, an important biomarker in SSc [6], in an SSc cohort treated with iloprost (and standard therapy; see Table 1), one of the most commonly used drugs that treats the vascular manifestation of SSc [21].